"Stack" is a word borrowed from bodybuilding, where it describes running several compounds at once. In the peptide market it has become a product category: named blends, sold under a single label, sometimes premixed in one vial.
This page sets out what those names refer to, where they come from, and what has actually been tested. The answer to the last question is unusually clean.
The census
We queried ClinicalTrials.gov on 16 September 2026 for each of the market's named combinations, pairing the components by intervention name. The results:
| Combination | Registered studies of the combination |
|---|---|
| CJC-1295 + ipamorelin | 0 |
| BPC-157 + TB-500 (the "Wolverine" pairing) | 0 |
| BPC-157 + thymosin beta-4 | 0 |
| GHK-Cu + BPC-157 | 0 |
| KPV + larazotide | 0 |
| sermorelin + ipamorelin | 0 |
A row of zeros is only interesting if the search would have found something. So the same census ran on the components individually:
| Component alone | Registered studies |
|---|---|
| larazotide | 10 |
| BPC-157 | 3 |
| ipamorelin | 2 |
| CJC-1295 | 1 |
| GHK-Cu | 1 |
| MOTS-c | 1 |
| Selank | 1 |
| KPV | 0 |
| epitalon | 0 |
| Semax | 0 |
The compounds are in the registry. They have simply never been registered together.
That finding is reproducible in a browser in about two minutes, and it is the single most useful fact about peptide stacks: every one of them is a commercial arrangement whose combined form has never entered formal testing anywhere, while several of its parts have.
Where the names come from
Not from pharmacology. "Wolverine" refers to the Marvel character whose defining trait is rapid regenerative healing — a description of a hoped-for outcome attached to a pair of molecules. "Glow" describes an appearance. "KLOW" is an acronym assembled from its asserted ingredients.
None of these names is a defined product, and none has a fixed composition. A clinic page for Wolverine Blend therapy, opened on 16 September 2026, describes it as "commonly described as a 'stack' combining BPC-157 (10mg) and TB-500 (10mg)" — the hedging in "commonly described as" is the clinic's own. Industry descriptions state the position plainly: because no official definition exists, the formulation varies depending on who offers it, and some versions add ipamorelin and CJC-1295.
The consequence is concrete. Two vials carrying the same stack name can contain different molecules at different ratios. What a fixed ratio does to the dose is worked through for KLOW and for the Wolverine pairing. A composition is asserted by whoever is selling, and there is no registry, monograph or label to check it against.
The claim a stack is sold on, and why component evidence cannot support it
The stated rationale for combining is consistent across sellers: the components act on overlapping but distinct pathways, producing a synergistic effect that neither achieves alone.
Read carefully, that is a claim about what happens when both are present. It is not a claim about either compound individually, and it cannot be evidenced by studies of either compound individually — those are what the claim is offered in place of.
The clinic page above illustrates the structure exactly. It cites no clinical trial of the combination; its supporting evidence is described as preclinical and early clinical work and animal models, for the individual peptides. That is an honest description of what exists. It is also, read precisely, a statement that the combination has no evidence behind it.
There is a second problem underneath the first. For a synergy argument to be interesting, each component needs an established effect to be synergistic with. Several of these do not have one in humans at all: on this site's own record, TB-500 has no human study of the fragment, KPV has 48 papers and no registration, and MOTS-c has no completed human trial. BPC-157's human record is one uncontrolled retrospective series. A synergy claim built on those is two unevidenced steps, not one.
Why "the parts are fine, so the whole is fine" does not hold
Combinations are not additive by default, and the regulated market is built around that fact rather than around a suspicion of it. Impurity thresholds, immunogenicity requirements and product-specific guidance all attach to a defined finished product — a particular formulation at a particular concentration — rather than to a list of ingredients. The reasoning is that interaction can occur in the tissue, in clearance, in immune recognition, and in the vial itself.
That last one matters for premixed blends specifically. When two peptides are combined into a single vial, the formulation is a new preparation: a new set of stability, solubility and degradation questions, none of which is answered by data on either peptide prepared alone. The testing page sets out what the standard research-grade analytical panel does and does not establish about a single-peptide vial; for a two-peptide vial, the same panel is being asked a harder question than it was designed for.
What is changing
One development is worth dating, because it is the first movement in years. Two of BPC-157's three registrations are recent orthopaedic filings — a rotator cuff repair study (NCT07803250) and an acute hamstring muscle strain study (NCT07437547). Both study BPC-157 on its own.
If those report, BPC-157 will have something it does not have today: a controlled human result for a stated indication. That would change the first half of a synergy argument. It would not change the second half, because they are not studies of a combination, and nothing registered anywhere currently is.
The summary a reader can carry
A peptide stack is a named commercial arrangement with no fixed composition, no registered study of the combination, and — for several of its common components — no human dose record for the individual compound either. The individual dose records this site holds are indexed on the peptide dosage chart, graded by where each figure came from. Where a blend's components are covered, the component pages are the honest unit: CJC-1295 and ipamorelin describes two compounds with human studies and a blend with none, which is the pattern in miniature.
Anything a reader is weighing about administration is a question for a clinician, not for a stack name.